Moderna expects 2025 revenue of $1.9B, above guidance

Moderna now expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its prior $1.6–$2.0 billion guidance, while raising 2025 GAAP operating expenses by $200 million to a $5.0–$5.2 billion range. The company projects year-end cash of roughly $8.1 billion, including a $0.6 billion draw from a $1.5 billion term loan, reiterated plans for up to 10% revenue growth in 2026 driven by continued COVID vaccine sales and potential seasonal flu/flu‑COVID launches, and flagged upcoming pivotal trial readouts in oncology, rare disease and infectious disease. Shares traded down about 3.3% intraday, reflecting mixed investor reaction to the revenue beat offset by higher operating expense guidance.

Analysis

Market structure: Moderna’s guidance ($1.9B rev vs prior midpoint $1.8B) and plan for up to 10% growth in 2026 reinforces vaccines as a recurring-revenue engine but also highlights a capital-light commercialization opportunity vs incumbent manufacturers (PFE, SNY). The $200M raise in GAAP op expense to $5–5.2B and $8.1B year-end cash (including $0.6B drawdown) signal a material mismatch between near-term cash generation and R&D/SG&A spend—pressure on margins and potential pricing or partnership moves over 12–24 months. Supply/demand: continued COVID sales + potential flu/COVID combo suggest stable seasonal demand for at-risk populations, but pricing power will hinge on approvals and payer acceptance vs cheaper incumbents.

Risk assessment: Tail risks include clinical/regulatory failures in oncology/rare-disease pivotal readouts (2026), a steep drop in COVID/flu demand, or equity dilution if cash runway shortens—each could move shares >40% within 6–12 months. Immediate risk window: Feb 13 Q4 report (earnings beat/miss + updated cash plan). Hidden dependencies: manufacturing scale, contract manufacturing relationships, and reimbursement decisions (CDC/WHO recommendations) that can abruptly change uptake in a season.

Trade implications: Tactical trades favor defined-risk option structures. Consider a modest directional exposure to MRNA with hedging: e.g., establish a 2–3% long position if price falls to $28–30 with a 20% stop, or buy a 9–12 month 30/20 protective put spread to cap downside at known cost. Pair trade: short MRNA vs long PFE (2:1 notional) to capture defensible cash flow and dividend stability if biotech risk premium re-expands. Avoid unhedged leaps into late-stage oncology binary risk ahead of readouts.

Contrarian angles: The market’s ~3% intraday decline is likely underreacting to the expense reset—MSFT-style cost cuts would be lauded, but Moderna’s $5B run-rate against <$2B revenue is a structural red flag; equity dilution or larger credit draw could be forthcoming. If readouts in 2026 are positive, upside could be >100%, so buy-write/call-spread structures (12–24 month) can monetize premium while preserving asymmetric upside. Historical parallel: vaccine franchises can become durable cash engines (e.g., GSK/HBV) but only after multi-year reimbursement alignment; don’t pay full valuation for presumptive execution.

Key Decisions for Investors

• If bullish on pipeline, initiate a limited 2–3% long position in MRNA at <$30 (or average down to $28) with a hard 20% stop-loss and hedge with a 6–12 month 30/20 put spread to limit downside to a known premium.
• Implement a pair trade: short MRNA (0.5–1.0% notional) vs long PFE (0.5–1.0%) for 3–6 months to profit from risk-off rotation and PFE’s stable cash flows; trim if MRNA falls >25% or if PFE underperforms by >10% relative.
• Use options to express binary views: buy a 12–18 month MRNA 45/70 call spread (reduce cost) sized at 0.5–1% portfolio risk to capture upside from positive 2026 pivotal readouts, and sell near-term (30–60 day) covered calls if holding stock into Feb 13 to harvest premium.
• Reduce speculative biotech exposure by 1–2% and reallocate to large-cap pharma (PFE, JNJ) or defensive healthcare for 3–12 months while monitoring Moderna’s Feb 13 Q4 report and 30–60 day regulatory updates on seasonal vaccine filings.
• Monitor three triggers over next 60 days before escalating positions: (1) Feb 13 Q4 results and cash runway disclosure; (2) any guidance/filing timeline for seasonal flu or combo vaccine approvals; (3) 2026 pivotal trial scheduling—if two of three are positive, consider increasing long exposure to 3–5%.